Panlong Pharmaceutical: Clinical trials of ibuprofen patches approved

Panlong Pharmaceutical Company announced that it recently received a "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration, approving the clinical trial of Flurbiprofen Patch. This product was developed by Japan's Taisho Pharmaceutical Co., Ltd. and was approved for sale in Japan on July 23, 1998. The indications for use include pain relief and anti-inflammatory effects for diseases and symptoms such as osteoarthritis, shoulder periarthritis, tendonitis and tenosynovitis, tendonitis, lateral epicondylitis, muscle pain, swelling and pain after injury. The original research for this project has not yet been marketed domestically, and it is registered as a Class 3 chemical drug. The product approved for clinical trials by the company this time is designed with a controlled release membrane, with the characteristics of a large drug load, low irritation, and less likely to cause skin allergies. It is particularly suitable for chronic pain diseases and situations where there is a higher demand for flexibility and high adhesion of the patch.